Rituximab is one of the drugs used to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) — cancers which typically affect elderly patients. Despite this treatment, however, some patients experience disease recurrence. Doctors are therefore seeking more effective therapies for these diseases.
In this study, investigators want to assess the effectiveness of adding the investigational drug CAL-101 to treatment with rituximab in elderly patients with CLL or SLL that has not yet been treated. CAL-101 works by inhibiting an enzyme called PI3 kinase, which fuels the growth of these cancers. The drug is taken orally (by mouth).